Reviva Pharmaceuticals (RVPH) Competitors $0.63 -0.02 (-3.75%) Closing price 04:00 PM EasternExtended Trading$0.62 -0.01 (-1.04%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RVPH vs. MOLN, GLSI, BTMD, SKYE, CRDF, CGEN, BHST, APLT, FATE, and IVVDShould you be buying Reviva Pharmaceuticals stock or one of its competitors? The main competitors of Reviva Pharmaceuticals include Molecular Partners (MOLN), Greenwich LifeSciences (GLSI), biote (BTMD), Skye Bioscience (SKYE), Cardiff Oncology (CRDF), Compugen (CGEN), BioHarvest Sciences (BHST), Applied Therapeutics (APLT), Fate Therapeutics (FATE), and Invivyd (IVVD). These companies are all part of the "pharmaceutical products" industry. Reviva Pharmaceuticals vs. Its Competitors Molecular Partners Greenwich LifeSciences biote Skye Bioscience Cardiff Oncology Compugen BioHarvest Sciences Applied Therapeutics Fate Therapeutics Invivyd Reviva Pharmaceuticals (NASDAQ:RVPH) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment. Which has preferable earnings & valuation, RVPH or MOLN? Reviva Pharmaceuticals has higher earnings, but lower revenue than Molecular Partners. Molecular Partners is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReviva PharmaceuticalsN/AN/A-$29.92M-$0.65-0.96Molecular Partners$5.65M27.62-$61.39M-$2.08-1.86 Do analysts prefer RVPH or MOLN? Reviva Pharmaceuticals currently has a consensus target price of $4.86, suggesting a potential upside of 676.52%. Molecular Partners has a consensus target price of $8.00, suggesting a potential upside of 106.99%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Reviva Pharmaceuticals is more favorable than Molecular Partners.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Reviva Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78Molecular Partners 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is RVPH or MOLN more profitable? Reviva Pharmaceuticals' return on equity of 0.00% beat Molecular Partners' return on equity.Company Net Margins Return on Equity Return on Assets Reviva PharmaceuticalsN/A N/A -259.17% Molecular Partners N/A -50.66%-45.13% Does the media refer more to RVPH or MOLN? In the previous week, Reviva Pharmaceuticals had 4 more articles in the media than Molecular Partners. MarketBeat recorded 6 mentions for Reviva Pharmaceuticals and 2 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 1.29 beat Reviva Pharmaceuticals' score of 0.74 indicating that Molecular Partners is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Reviva Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Molecular Partners 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of RVPH or MOLN? 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 26.6% of Molecular Partners shares are held by institutional investors. 27.2% of Reviva Pharmaceuticals shares are held by insiders. Comparatively, 5.9% of Molecular Partners shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, RVPH or MOLN? Reviva Pharmaceuticals has a beta of -0.08, indicating that its share price is 108% less volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. SummaryReviva Pharmaceuticals beats Molecular Partners on 10 of the 14 factors compared between the two stocks. Get Reviva Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RVPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RVPH vs. The Competition Export to ExcelMetricReviva PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.37M$2.62B$6.05B$10.45BDividend YieldN/A57.77%5.73%4.79%P/E Ratio-0.9622.5285.2827.12Price / SalesN/A637.32587.61188.70Price / CashN/A25.7125.7330.17Price / Book31.285.3212.656.69Net Income-$29.92M$32.98M$3.31B$276.03M7 Day Performance-6.54%1.39%-0.38%-1.13%1 Month Performance41.42%10.08%8.77%6.48%1 Year Performance-48.73%-0.32%76.80%34.34% Reviva Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RVPHReviva Pharmaceuticals3.6465 of 5 stars$0.63-3.8%$4.86+676.5%-46.7%$43.37MN/A-0.965Gap UpHigh Trading VolumeMOLNMolecular Partners1.6543 of 5 stars$3.72+0.3%$8.00+115.0%-19.8%$149.79M$5.65M-1.79180GLSIGreenwich LifeSciences1.1051 of 5 stars$11.28+3.4%$42.00+272.3%-22.4%$148.71MN/A-8.293BTMDbiote2.3267 of 5 stars$2.91-2.3%$6.00+106.2%-47.3%$147.33M$197.19M3.23194SKYESkye Bioscience2.4935 of 5 stars$1.90-60.0%$9.80+415.8%-59.7%$147.20MN/A-1.7911Gap DownHigh Trading VolumeCRDFCardiff Oncology2.3409 of 5 stars$2.20+0.5%$10.63+383.0%-16.0%$145.69M$680K-2.5320News CoverageCGENCompugen1.3261 of 5 stars$1.79+9.8%$4.00+123.5%+7.6%$145.46M$27.86M-8.1470News CoverageGap UpBHSTBioHarvest Sciences1.8961 of 5 stars$9.85+12.3%$13.67+38.7%N/A$144.05M$25.19M-14.07N/AHigh Trading VolumeAPLTApplied Therapeutics3.7598 of 5 stars$1.02+2.0%$4.13+304.4%-89.0%$144.01M$460K-2.2730Positive NewsFATEFate Therapeutics3.8861 of 5 stars$1.41+16.5%$3.30+134.0%-47.1%$139.55M$13.63M-0.97550High Trading VolumeIVVDInvivyd3.4939 of 5 stars$1.42+22.4%$5.14+261.8%+72.5%$139.37M$25.38M-1.54100High Trading Volume Related Companies and Tools Related Companies MOLN Alternatives GLSI Alternatives BTMD Alternatives SKYE Alternatives CRDF Alternatives CGEN Alternatives BHST Alternatives APLT Alternatives FATE Alternatives IVVD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RVPH) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reviva Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
